Maze Therapeutics Announces Publication of Research Demonstrating Newly Identified Variant for APOL1 Kidney Disease is Associated with Reduced Risk of APOL1 Kidney Disease

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced the publication of research validating the protective role and mechanism of an APOL1 genetic variant– p.N264K— in chronic kidney disease (CDK) and end stage kidney disease (ESKD) among carriers with high-risk variants. The…
Click here to view original post